Kariem Ezzat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9185463/publications.pdf

Version: 2024-02-01

361045 500791 2,081 29 20 28 h-index citations g-index papers 32 32 32 2963 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Proteins Do Not Replicate, They Precipitate: Phase Transition and Loss of Function Toxicity in Amyloid Pathologies. Biology, 2022, 11, 535. | 1.3 | 14 |
| 2 | High cerebrospinal amyloid- \hat{l}^2 42 is associated with normal cognition in individuals with brain amyloidosis. EClinicalMedicine, 2021, 38, 100988. | 3.2 | 69 |
| 3 | Novel Orthogonally Hydrocarbon-Modified Cell-Penetrating Peptide Nanoparticles Mediate Efficient Delivery of Splice-Switching Antisense Oligonucleotides In Vitro and In Vivo. Biomedicines, 2021, 9, 1046. | 1.4 | 6 |
| 4 | Does the Anti‶au Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? Yes. Movement Disorders Clinical Practice, 2021, 8, 1034-1037. | 0.8 | 2 |
| 5 | Soluble Amyloid-β Consumption in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, 1403-1415. | 1.2 | 31 |
| 6 | Extracellular amyloid deposition in sporadic inclusion body myositis: Further insights. Muscle and Nerve, 2021, 64, 517-519. | 1.0 | 0 |
| 7 | Low soluble amyloid- \hat{l}^2 42 is associated with smaller brain volume in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 92, 15-21. | 1.1 | 8 |
| 8 | Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP). Frontiers in Aging Neuroscience, 2020, 12, 553635. | 1.7 | 22 |
| 9 | Disentangling the Amyloid Pathways: A Mechanistic Approach to Etiology. Frontiers in Neuroscience, 2020, 14, 256. | 1.4 | 21 |
| 10 | The viral protein corona directs viral pathogenesis and amyloid aggregation. Nature Communications, 2019, 10, 2331. | 5.8 | 160 |
| 11 | Degradation of pristine and oxidized single wall carbon nanotubes by CYP3A4. Biochemical and Biophysical Research Communications, 2019, 515, 487-492. | 1.0 | 4 |
| 12 | Novel peptide-dendrimer/lipid/oligonucleotide ternary complexes for efficient cellular uptake and improved splice-switching activity. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 132, 29-40. | 2.0 | 17 |
| 13 | C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain, 2017, 140, 887-897. | 3.7 | 126 |
| 14 | Role of autophagy in cell-penetrating peptide transfection model. Scientific Reports, 2017, 7, 12635. | 1.6 | 23 |
| 15 | Peptides for nucleic acid delivery. Advanced Drug Delivery Reviews, 2016, 106, 172-182. | 6.6 | 174 |
| 16 | Synthetic SiRNA Delivery: Progress and Prospects. Methods in Molecular Biology, 2016, 1364, 291-310. | 0.4 | 39 |
| 17 | The role of endocytosis in the uptake and intracellular trafficking of PepFect14–nucleic acid nanocomplexes via class A scavenger receptors. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 3205-3216. | 1.4 | 17 |
| 18 | Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nature Medicine, 2015, 21, 270-275. | 15.2 | 263 |

| # | Article | IF | CITATION |
|----|--|-----|----------|
| 19 | Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides. Nano Letters, 2015, 15, 4364-4373. | 4.5 | 80 |
| 20 | A convergent uptake route for peptide- and polymer-based nucleotide delivery systems. Journal of Controlled Release, 2015, 206, 58-66. | 4.8 | 35 |
| 21 | PepFect14 Peptide Vector for Efficient Gene Delivery in Cell Cultures. Molecular Pharmaceutics, 2013, 10, 199-210. | 2.3 | 83 |
| 22 | Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. Journal of Controlled Release, 2012, 162, 1-8. | 4.8 | 51 |
| 23 | Scavenger receptorâ€mediated uptake of cellâ€penetrating peptide nanocomplexes with oligonucleotides. FASEB Journal, 2012, 26, 1172-1180. | 0.2 | 127 |
| 24 | Peptide Nanoparticles for Oligonucleotide Delivery. Progress in Molecular Biology and Translational Science, 2011, 104, 397-426. | 0.9 | 13 |
| 25 | Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Research, 2011, 39, 3972-3987. | 6.5 | 262 |
| 26 | A Peptide-based Vector for Efficient Gene Transfer In Vitro and In Vivo. Molecular Therapy, 2011, 19, 1457-1467. | 3.7 | 94 |
| 27 | PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Research, 2011, 39, 5284-5298. | 6.5 | 199 |
| 28 | Peptide-Based Matrices as Drug Delivery Vehicles. Current Pharmaceutical Design, 2010, 16, 1167-1178. | 0.9 | 27 |
| 29 | Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy. Journal of Controlled Release, 2010, 141, 42-51. | 4.8 | 113 |